Predictors of Cardiac Arrhythmia in Rheumatoid Arthritis Patients

NCT07782788 | Not Yet Recruiting

• 1 other identifier: 04-2026-201765
• Study Type: observational
• Target: 120
• Locations: 0 countries
• Sites: N/A

Brief Summary

To evaluate QT dispersion, P-wave dispersion and Tp-e dispersion as predictors of cardiac arrhythmias in patients with rheumatoid arthritis and to assess their relationship with disease characteristics and inflammatory activity

Conditions

Rheumatoid Arthritis (RA)

Outcome Measures

Primary Outcomes (1)

• QT dispersion, P-wave dispersion and Tp-e dispersion

  to assess QT dispersion , P wave dispersion and Tp-e dispersion on 12 lead ECG and compare their values between rheumatoid arthritis patients and healthy controls and to evaluate their association with the risk of cardiac arrhythmia

  baseline

Secondary Outcomes (1)

• Correlation between ECG parameters and disease activity assessed by DAS28

  at baseline

Study Arms (2)

group 1 rheumatoid arthritis patients

rheumatoid arthritis patients diagnosed according to 2010 ACR\\EULAR criteria

group 2 healthy controls

healthy controls without RA meeting study eligibility criteria

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

adult male and female participants aged ≥18 years, including patients with rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria and age- and sex matched healthy controls. Participants with other autoimmune diseases, thyroid disorders, cardiac diseases, electrolyte abnormalities (hypocalcemia, hypokalemia, or hypomagnesemia), or use of drugs known to affect cardiac rhythm such as amiodarone will be excluded

You may qualify if:

• Patients diagnosed with rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria
• Age ≥18 years
• Male and female patients

You may not qualify if:

• Presence of other autoimmune diseases
• Thyroid disorders
• Use of medications affecting cardiac conduction or repolarization such as amiodarone and other antiarrhythmic drugs
• Electrolyte disturbances including hypocalcemia, hypokalemia and hypomagnesemia
• Known cardiac diseases including ischemic heart disease, valvular heart disease, cardiomyopathy, heart failure or congenital heart disease

Sponsors & Collaborators

• Assiut University: lead

Related Publications (2)

• Cindas A, Gokce-Kutsal Y, Tokgozoglu L, Karanfil A. QT dispersion and cardiac involvement in patients with rheumatoid arthritis. Scand J Rheumatol. 2002;31(1):22-6. doi: 10.1080/030097402317255327.

  PMID: 11922196 RESULT

• Gulkesen A, Yildirim Uslu E, Akgol G, Alkan G, Kobat MA, Gelen MA, Uslu MF. Is the development of arrhythmia predictable in rheumatoid arthritis? Arch Rheumatol. 2024 Aug 26;39(3):429-435. doi: 10.46497/ArchRheumatol.2024.10590. eCollection 2024 Sep.

  PMID: 39507840 RESULT

MeSH Terms

Conditions

Arthritis, Rheumatoid

Condition Hierarchy (Ancestors)

Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases

Study Officials

• katreen N henin, master

  faculty of medicine , Assiut university ,Eygpt

  PRINCIPAL INVESTIGATOR

Central Study Contacts

katreen N henin, master

CONTACT

+2001553202412; Katrin.18313203@med.aun.edu.eg

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident Physician

Study Record Dates

• First Submitted: August 20, 2026
• First Posted: August 24, 2026
• Study Start (Estimated): October 1, 2026
• Primary Completion (Estimated): October 1, 2027
• Study Completion (Estimated): November 1, 2027
• Last Updated: August 24, 2026

Record last verified: 2026-08

Data Sharing

• IPD Sharing: Will not share